1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

28 Feb 2020
Admin
News Article

Glenmark Inks Licensing Pact With Hikma For Commercialisation Of Nasal Spray Ryaltris In Us

Glenmark Pharmaceuticals On Thursday Said It Has Entered Into An Exclusive Licensing Agreement With Hikma Pharmaceuticals Plc For Commercialising Its Novel Nasal Spray Ryaltris In The Us.The Company, However, Did Not Disclose The Amount That It Stands To Receive From Hikma.The Licensing Pact For Ryaltris Has Been Signed Between The Company'S Swiss Subsidiary, Glenmark Specialty Sa And Hikma Pharmaceuticals Plc (Hikma).Ryaltris Is A Novel Fixed-Dose Combination Nasal Spray Of An Anti-Histamine And A Steroid, Indicated For Treatment Of Symptoms Associated With Seasonal Allergic Rhinitis (Sar) In Patients Over 12 Years Of Age.Under The Terms Of The Agreement, Mumbai-Based Glenmark Will Be Responsible For The Continued Development And Regulatory Approval Of Ryaltris By The Us Food And Drug Administration (Usfda).Hikma Will Be Responsible For The Commercialisation Of Ryaltris In The Us Following Approval. Hikma Would Also Have The Ability To Produce The Product Utilizing Its Nasal Manufacturing Capabilities In Columbus, Ohio, It Added.Glenmark Said Will Receive An Upfront Payment, Regulatory Approval And Commercial Milestone Payments As Well As Royalties From Hikma For Ryaltris.The Agreement With Hikma Is Glenmark'S Fourth Regional Licensing Deal For Ryaltris. The Company Has Already Signed Licensing Deals For Commercialising Ryaltris In China, Australia, New Zealand And South Korea."We Are Happy To Partner With Hikma In The Us As Ryaltris Is A Perfect Strategic Fit In Their Near-Term Plan To Build A Branded Nasal Spray Portfolio. This Partnership Gives Us An Opportunity To Tap Into The Largest Pharmaceutical Market In The World," Glenmark Pharmaceuticals Chairman And Md Glenn Saldanha Said."This Step Is Aligned With Our Vision To Make Ryaltris The First Global Brand Of Glenmark By Launching It In Several Markets Across The Globe," He Added.Hikma Generics President Brian Hoffmann Said Hikma Is The Largest Supplier Of Generic Nasal Sprays In The Us And Adding Ryaltris Is A Significant Step Forward In Expanding The Company'S Us Nasal Spray Leadership Into Branded Medicines."It Will Allow Us To Leverage Our Strong, Existing Specialty Salesforce Already Calling On Doctors With Our Specialty Portfolio, And To Potentially Leverage Our Nasal Spray Manufacturing Capabilities In Columbus, Ohio. We Look Forward To Bringing This Important New Treatment Option To Millions Of Us Patients," Hoffmann Added. Rkl Rkl Anu Anu

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!